{
  "id": 7225052,
  "title": "First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer",
  "url": "https://urgent.news/2026/09/14/first-line-trastuzumab-deruxtecan-significantly-improves-progression",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T01:50:08.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-line-trastuzumab-deruxtecan-significantly-free.html"
  },
  "original_language": "en",
  "account": "In a groundbreaking phase 3 trial, trastuzumab deruxtecan (T-DXd) demonstrated superior results compared to the standard therapy of pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC). The DESTINY-Lung04 trial, a global study, showed that T-DXd led to a significant 6-month improvement in median progression-free survival, which increased from 8.3 months to 14.3 months. Additionally, T-DXd produced a higher objective response rate of 70.0% compared to 44.5% with the standard treatment. Despite these improvements, overall survival was not significantly affected by T-DXd, and a notable side effect was interstitial lung disease/pneumonitis, which occurred in 20.8% of T-DXd patients compared to 2.3% in the standard treatment group. These findings suggest that T-DXd could be a promising new option for first-line treatment of HER2-mutant NSCLC, addressing the need for more effective HER2-directed therapies.",
  "summary": "First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to primary results from the phase 3 DESTINY-Lung04 trial presented at the International Association for the Study of Lung Cancer…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}